StockWatch
·
Biotechnology: Pharmaceutical Preparations
RegulatoryNov 17, 2026, 04:06 PM

Amneal Pharmaceuticals: European Commission Approves Adcomfo Biosimilar

AI Summary

Amneal Pharmaceuticals announced that the European Commission has granted marketing authorization for Adcomfo® (omalizumab), a biosimilar to XOLAIR®. This approval follows authorization from the UK MHRA in March 2026 and a positive opinion from the EMA's CHMP in September 2026. Amneal acquired the developer, Kashiv BioSciences, in August 2026. The company also noted that its U.S. Biologics License Application for the same biosimilar is currently under review by the FDA. Adcomfo is indicated for severe persistent allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic spontaneous urticaria.

Key Highlights

  • European Commission grants marketing authorization for Adcomfo® (omalizumab), a biosimilar to XOLAIR®.
  • Adcomfo® also received authorization from the UK MHRA in March 2026.
  • Amneal acquired Kashiv BioSciences, the developer of Adcomfo®, in August 2026.
  • U.S. application for Amneal's proposed biosimilar to XOLAIR® is currently under FDA review.
  • Adcomfo® is approved for severe persistent allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic spontaneous urticaria.
  • The drug is available in 75 mg, 150 mg, and 300 mg presentations in pre-filled syringe and pen configurations.